City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border 		  
   
The following is a list of available studies directed by  Robert Figlin, MD  
Search results:  3  Clinical trial(s) found  (Page 1 of 1 )
 
Click here to generate a printer-friendly view  
 08130
   P.I.: Robert Figlin, MD
Title: A Randomized Open Label, Multi-Center Phase II Study to Compare Bevacizumab Plus RAD001 Versus Interferon Alfa-2A Plus Bevacizumab for the First-Line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney
 
Click here for  Full Eligibility Criteria
 07124
   P.I.: Robert Figlin, MD
Title: A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy
 
Click here for  Full Eligibility Criteria
 06090
   P.I.: Robert Figlin, MD
Title: CTSU/ECOG E2805: A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
 
Click here for  Full Eligibility Criteria
 

  
© 2009 City of Hope.
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.